Read by QxMD icon Read

Her2 negative breast cancer

A Mariamidze, L Gogiashvili, O Khardzeishvili, T Javakhishvili, D Makaridze, K Jandieri
The analysis of prevalence of each specific subtypes of the ductal invasive breast carcinoma according to age group categories showed that Luminal A subtype is observed in every age group as dominant subtype, although in different intensity: two peaks were demonstrated in group III and group IV, and in relatively less amount, in V group as well. Its considerable that Her2(+)/ER subtype was second most prevalent subtype in almost all age groups. It also must be noted that there was no direct correlation found between pre- or post-menopausal period and HER2+ state, except for group IV (60-69 year old range), where it was almost 2 times less frequently found than Basal-like subtype...
October 2018: Georgian Medical News
Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda, Shoichiro Ohtani, Shinji Ohno, Masato Takahashi, Yutaka Yamamoto, Reiki Nishimura, Nobuaki Sato, Shozo Ohsumi, Hiroji Iwata, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Takashi Nagasawa, Yoshiko Umeyama, Dongrui R Lu, Masakazu Toi
BACKGROUND: In PALOMA-2, palbociclib-letrozole significantly improved progression-free survival (PFS) vs placebo-letrozole in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC) in the first-line setting. We evaluated the efficacy, safety, and pharmacokinetics of palbociclib in Japanese women in PALOMA-2. METHODS: In this phase 3 study, 666 postmenopausal women with ER+/HER2- ABC were randomized 2:1 to palbociclib (125 mg/day [3 weeks on/1 week off]) plus letrozole (2...
December 4, 2018: International Journal of Clinical Oncology
Soizic Garaud, Pawel Zayakin, Laurence Buisseret, Undine Rulle, Karina Silina, Alexandre de Wind, Gert Van den Eyden, Denis Larsimont, Karen Willard-Gallo, Aija Linē
An important role for tumor infiltrating B lymphocytes (TIL-B) in the immune response to cancer is emerging; however, very little is known about the antigen specificity of antibodies produced in situ . The presence of IgA antibodies in the tumor microenvironment has been noted although their biological functions and clinical significance are unknown. This study used a 91-antigen microarray to examine the IgG and IgA autoantibody repertoires in breast cancer (BC). Tumor and adjacent breast tissue supernatants and plasma from BC patients together with normal breast tissue supernatants and plasma from healthy controls (patients undergoing mammary reduction and healthy blood donors) were analyzed to investigate relationships between autoantibodies and the clinical, histological and immunological features of tumors...
2018: Frontiers in Immunology
Cristina Guarducci, Martina Bonechi, Matteo Benelli, Chiara Biagioni, Giulia Boccalini, Dario Romagnoli, Roberto Verardo, Rachel Schiff, C Kent Osborne, Carmine De Angelis, Angelo Di Leo, Luca Malorni, Ilenia Migliaccio
CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+), HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to these agents is universal. Here, we profiled a large panel of HR+ BC cell lines with conditioned resistance to the CDK4/6 inhibitor palbociclib, and analyzed cell cycle-related markers by gene expression profiles (GEP) and western blot (WB). GEP showed high molecular heterogeneity among the models, with E2F targets being significantly enriched both during treatment and at the time of resistance...
2018: NPJ Breast Cancer
Irma Soldevilla-Gallardo, Sevastian S Medina-Ornelas, Cynthia Villarreal-Garza, Enrique Bargalló-Rocha, Claudia Hs Caro-Sánchez, Rodrigo Hernández-Ramírez, Enrique Estrada-Lobato
Our study examines the association between two Positron Emission Mammography (PEM) semi-quantitative parameters: PUVmax (maximum uptake value) and LTB (lesion to background) baseline and the end of Neoadjuvant chemotherapy (NAC) with pathologic response in each of the following breast cancer subtype: Triple negative breast cancer (TPN), HER2-positive, and ER-positive/HER2-negative cancers. One-hundred and eight patients, 71 with invasive ductal carcinoma and 37 with infiltrating lobular carcinoma were evaluate with 18 F-FDG-PEM scans before and after of NAC...
2018: American Journal of Nuclear Medicine and Molecular Imaging
Tingting Zhang, Fubin Feng, Wenge Zhao, Yan Yao, Jinhui Tian, Chao Zhou, Chuanxin Zang, Cun Liu, Xue Wang, Changgang Sun
Background: We performed a network meta-analysis of randomized controlled trials (RCTs) to indirectly compare the efficacy of different targeted agents with fulvestrant for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor type 2-negative (HER2-) advanced breast cancer (ABC) following progression on prior endocrine therapy. Methods: The titles/abstracts were searched from the PubMed, EMBASE, and the Cochrane Library databases for RCTs to evaluate the efficacy of palbociclib plus fulvestrant vs alternative targeted therapies plus fulvestrant for postmenopausal HR+/HER2- ABC following progression on prior endocrine therapy...
2018: Cancer Management and Research
Andrea Breaux, Bradley Turner, Xiaoyong Wu, Shesh N Rai, Elizabeth C Riley, Mounika Mandadi, Mary Ann Sanders
PURPOSE: The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system requires histologic grade (GR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and stage (assessed by the tumor, node, metastasis classification system). For T1-2 N0, ER+ /HER2- tumors, if the 21-gene expression assay is ordered and Oncotype DX (ODX) recurrence score (RS) is 0 to 10, the stage is IA. The purpose of this study was to determine the impact of the ODXRS on staging ER+ /HER2- tumors...
October 29, 2018: Clinical Breast Cancer
Yu Deng, Jialing Zou, Ting Deng, Junying Liu
BACKGROUND: Previous studies examining the prognostic value of glucose transporter 1 in breast cancer have yielded inconsistent results. We, therefore, performed a meta-analysis to clarify this issue. METHODS: The research was reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Relevant studies were retrieved from PubMed, Web of Science, EMBASE, and Cochrane library. RESULTS: A total of 7 reports with 1861 patients were finally chosen...
November 2018: Medicine (Baltimore)
Tanja Fehm, Volkmar Müller
Within the last years significant improvements have been achieved in early and metastatic breast cancer treatment by innovative targeted therapies and new drug combinations. GnRH-analogues have been confirmed as an important part of endocrine treatment in premenopausal patients. Endocrine based strategies including CDK-4/6-Inhibitors substantially improve progression-free survival in metastatic patients. For patients with HER2-positive disease the addition of Pertuzumab to Trastuzumab in combination with chemotherapy has achieved a significant improvement in anti-HER2 therapy in early as well as metastatic breast cancer...
December 2018: Deutsche Medizinische Wochenschrift
Sheridan M Hoy
Talazoparib (TALZENNA™) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks. It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer (as detected by a US FDA-approved assay). A regulatory assessment for talazoparib in this patient population is underway in the EU, with talazoparib also undergoing development for use in metastatic castration-resistant prostate cancer and various solid tumours, and as neoadjuvant therapy in early triple negative breast cancer...
November 30, 2018: Drugs
Mark K Farrugia, Sinjen Wen, Geraldine M Jacobson, Mohamad Adham Salkeni
Neoadjuvant chemotherapy (NAC) is a significant modality in breast cancer therapy. We sought to characterize prognostic factors in patients scheduled for NAC who had a pretreatment positron-emission tomography paired with diagnostic quality contrast-enhanced computed tomography (CT) (positron-emission tomography/CT [PET/CT]). A total of 118 breast cancer patients were analyzed through chart review who underwent pretreatment PET/CT imaging and received NAC from 2008 to 2014. We collected information on molecular markers, PET/CT, pathologic complete response (pCR), survival, and disease status...
October 2018: World Journal of Nuclear Medicine
Lenora W M Loo, Makana Williams, Brenda Y Hernandez
BACKGROUND: While breast cancer incidence and mortality rates differ across racial/ethnic populations in the U.S., little is known about Asian and Pacific Island subpopulations. Hawaii is one of the most racially/ethnically diverse states in the U.S. Overall, Hawaii ranks 5th highest for breast cancer incidence in the nation (2010-2014) and rates have increased in recent years despite a stable national trend. In contrast, for breast cancer mortality, Hawaii has the 3rd lowest rate in the nation, with rates demonstrating a steady decline for nearly 3 decades...
November 29, 2018: Cancer Epidemiology
Julieta Leone, Ariel O Zwenger, Bernardo A Leone, Carlos T Vallejo, José P Leone
OBJECTIVES: To analyze differences in overall survival (OS) between male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype compared with other factors. MATERIALS AND METHODS: We evaluated men and women with breast cancer between 2010 and 2013 with known hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results program...
November 28, 2018: American Journal of Clinical Oncology
Kalpalata Tripathy, Aparajita Mishra, Ajit K Singh, Pragnya L Panda, Arup Mahapatra, Anusaya Lenka
Context: Efficacy of immunocytochemistry (ICC) in determining molecular biomarkers like estrogen receptor (ER), progesterone receptors (PRs), and human epidermal growth factor receptor-2 (HER2). Aims: To evaluate biomarkers using ICC in breast cancer as per American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) guidelines. Settings and Design: The study was conducted over a period of 2 years from September 2012 to August 2014 and is the first such study in eastern India...
October 2018: Journal of Cytology
Elen Kristine Höglander, Silje Nord, David C Wedge, Ole Christian Lingjærde, Laxmi Silwal-Pandit, Hedda vdL Gythfeldt, Hans Kristian Moen Vollan, Thomas Fleischer, Marit Krohn, Ellen Schlitchting, Elin Borgen, Øystein Garred, Marit M Holmen, Erik Wist, Bjørn Naume, Peter Van Loo, Anne-Lise Børresen-Dale, Olav Engebraaten, Vessela Kristensen
BACKGROUND: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels. METHODS: A phase II randomized clinical trial of 123 patients with Her2-negative breast cancer was conducted, with patients treated with neoadjuvant chemotherapy (fluorouracil (5FU)/epirubicin/cyclophosphamide (FEC) and taxane), with or without bevacizumab...
November 29, 2018: Genome Medicine
Yunlei Zhang, Qianqian Ni, Chaoli Xu, Bing Wan, Yuanyuan Geng, Gang Zheng, Jun Tao, Zhenlu Yang, Ying Zhao, Jun Wen, Junjie Zhang, Shouju Wang, Yuxia Tang, Yanju Li, Qirui Zhang, Li Liu, Zhaogang Teng, Guangming Lu
Supersensitive magnetic resonance (MR) imaging requires contrast with extremely high r2 values. However, synthesized magnetic nanoparticles generally have a relatively low r2 relaxivity. Magnetosomes with high saturation magnetization and good biocompatibility have shown potential value as MR imaging contrast agents. Magnetosomes that target human epidermal growth factor receptor-2 (HER2) were prepared using genetic technology and low-frequency sonication. Anti-HER2 affibody of the ability to target HER2 was displayed on membrane surface of the magnetosomes through the anchor protein MamC, allowing the bacterial nanoparticles to target tumors overexpressing HER2...
November 29, 2018: ACS Applied Materials & Interfaces
Chunyan He, Rina Plattner, Vivek Rangnekar, Binhua Zhou, Chunming Liu, Rachel L Stewart, Bin Huang, Chi Wang, Thomas C Tucker
BACKGROUND: We evaluated five key proteins involved in various cancer-related pathways and assessed their relation to breast cancer recurrence. METHODS: We used the Kentucky Cancer Registry to retrospectively identify primary invasive breast cancer cases (n = 475) that were diagnosed and treated at University of Kentucky Medical Center between 2000 and 2007. Breast cancer recurrence was observed in 62 cases during the 5-year follow-up after diagnosis. Protein expression or activity level was analyzed from surgery tissue using immuno-histochemical assays...
November 28, 2018: Cancer Causes & Control: CCC
Jingjing Xie, Zhongyuan Xu
BACKGROUND: Population-based estimates for prognosis among patients with liver metastases in newly diagnosed breast cancer are not generally available. METHODS: Within the Surveillance, Epidemiology and End Results (SEER) database, we identified 298,370 breast cancer patients and 4,285 patients diagnosed with initial liver metastases between 2010 and 2014. Data were stratified according to subtype, age and race. Multivariate logistic and Cox regression were used to identify predictors for the presence of initial liver metastases and prognostic factors, respectively...
November 28, 2018: Cancer Epidemiology, Biomarkers & Prevention
Sopit Tubtimhin, Supannee Promthet, Krittika Suwanrungruang, Pongsatorn Supaattagorn
Background and Purpose: This study focused on molecular subtypes and prognostic factors for survival of preand post-menopausal breast cancer patients. Methods: A retrospective cohort study was performed on 523 patients with invasive carcinoma of the breast treated at Ubon Ratchathani Cancer Hospital,Thailand from 2002 to 2016. Patient characteristics were collected based on a systematic chart audit from medical records. Prognostic factors were performed by observe survival analysis. A Cox regression model was used to calculate hazard ratios of death, taking into account the age and menopause status, molecular subtype, stage of disease, histological grade, lymphatic and vascular invasion, resection margin, hormone receptor expression, and treatment modality...
November 29, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
Daniel Migliozzi, Huu T Nguyen, Martin A M Gijs
Immunohistochemistry (IHC) is one of the main clinical techniques for biomarker assessment on tissue biopsies. It consists in chromogenic labeling with specific antibodies, followed by optical imaging, and it is used for diagnosis and therapeutic targeting. A well-known drawback of IHC is its limited robustness, which often precludes quantitative biomarker assessment. We combine microfluidic immunostaining, fluorescence imaging, and image-based cell segmentation to create an ultrafast procedure for accurate biomarker assessment via IHC...
November 2018: Journal of Biomedical Optics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"